Letters sent to healthcare professionals in August 2016

A summary of safety letters sent to healthcare professionals in August 2016

• From: Medicines and Healthcare products Regulatory Agency
• Published: 15 September 2016

• Therapeutic area: Cancer

In August 2016, a letter was sent to relevant healthcare professionals to inform them of the outcome of a review of the safety of idelalisib (Zydelig▼), including the risk of infection.

See also a Drug Safety Update article on the outcome of the safety review.

Article citation: Drug Safety Update volume 10 issue 2, September 2016: 4.

Published 15 September 2016